These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Healthcare stocks are often labelled as "underrepresented" on the Australian stock market. 

That's because compared to other sectors like financials (big banks) and resources (mining and energy), healthcare makes up a much smaller portion of the ASX's total market capitalisation.

For example, financials and materials can account for 50–60% of the ASX 200, while healthcare often contributes around 10–12%, depending on market conditions.

Furthermore, the healthcare sector on the ASX is dominated by a few major companies:

  • CSL Ltd (ASX: CSL) – one of Australia's largest companies, and by far the biggest healthcare stock.
  • Cochlear Ltd (ASX: COH), ResMed Inc (ASX: RMD), and Sigma Healthcare Ltd (ASX: SIG) are also prominent.

This means the sector's performance is heavily tied to these few holdings, making it less diversified than in other markets like the US.

However, that also means there are hundreds of growth stocks with the potential to bring large returns. 

Let's look at two that are tipped for growth according to broker Bell Potter. 

Broker looking at the share price on her laptop with green and red points in the background.

Image source: Getty Images

Clinuvel Pharmaceuticals Ltd (ASX: CUV)

This biopharmaceutical company develops and commercialises treatments for rare genetic and skin disorders, especially those related to light sensitivity.

This healthcare stock has seen its share price fall 34.53% over the last year. 

However, Bell Potter sees opportunity in this healthcare stock. 

The broker maintains its "buy" recommendation and $21.45. 

At the time of writing, shares are trading at $9.99 each, which indicates an upside of approximately 117.7%. 

The company is optimistic thanks to the company's lean, vertically integrated business model. 

Furthermore, the broker noted that the company commercialises Scenesse, the only approved drug in the US and EU for patients with EPP (Erythropoietic protoporphyria). 

Cyclopharm Ltd (ASX: CYC)

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in diagnostic imaging in lung health. It manufactures and sells medical devices and pharmaceutical products.

At the time of writing, CYC shares are down 42.86% in the past year. 

This significant drop might mean it's been oversold, with Bell Potter placing a "buy" recommendation and $2.20 price target. 

This indicates a 134.0% upside from its current price of $0.94. 

A report from the broker last month highlighted the company has experienced slower than expected growth. 

However, the underlying U.S. market opportunity remains significant according to Bell Potter. 

Investors should be also aware that growth stocks can come with increased upside, but simultaneously more volatility.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »